一种在肺腺癌中发现的新型EML4-ALK与BIRC6-ALK双融合变体对阿来替尼敏感。 - Suppr

A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib.

作者信息

Zhong Jiang-Ming, Zhang Gui-Feng, Lin Li, Li De-Yu, Liu Zhen-Hua

机构信息

Department of Medical Oncology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian, PR China.

出版信息

Lung Cancer. 2020 Jul;145:211-212. doi: 10.1016/j.lungcan.2020.04.030. Epub 2020 May 4.

DOI:10.1016/j.lungcan.2020.04.030

PMID:32409002

Abstract

摘要

相似文献

A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib.

Lung Cancer. 2020 Jul;145:211-212. doi: 10.1016/j.lungcan.2020.04.030. Epub 2020 May 4.

Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.

Thorac Cancer. 2018 Oct;9(10):1327-1332. doi: 10.1111/1759-7714.12834. Epub 2018 Aug 21.

A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.

J Natl Compr Canc Netw. 2021 Nov 11;20(1):2-6. doi: 10.6004/jnccn.2021.7077.

Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.

Lung Cancer. 2021 Dec;162:86-89. doi: 10.1016/j.lungcan.2021.10.015. Epub 2021 Nov 5.

Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.

Lung Cancer. 2021 Oct;160:32-35. doi: 10.1016/j.lungcan.2021.07.020. Epub 2021 Aug 6.

EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib.

BMJ Case Rep. 2021 Apr 27;14(4):e240295. doi: 10.1136/bcr-2020-240295.

EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature.

Clin Lung Cancer. 2020 Nov;21(6):e597-e600. doi: 10.1016/j.cllc.2020.05.016. Epub 2020 May 23.

ALK-rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib.

Thorac Cancer. 2022 Apr;13(7):1095-1097. doi: 10.1111/1759-7714.14347. Epub 2022 Feb 11.

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.

J Thorac Oncol. 2019 Jul;14(7):1233-1243. doi: 10.1016/j.jtho.2019.03.007. Epub 2019 Mar 20.

Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion.

Invest New Drugs. 2022 Oct;40(5):1160-1163. doi: 10.1007/s10637-022-01260-4. Epub 2022 May 24.

引用本文的文献

Coexistence of a novel , double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review.

Front Oncol. 2024 Dec 13;14:1453259. doi: 10.3389/fonc.2024.1453259. eCollection 2024.

Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review.

Discov Oncol. 2024 Feb 20;15(1):43. doi: 10.1007/s12672-024-00899-0.

Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase () rearrangements and co-existing alterations-a retrospective cohort study.

Transl Lung Cancer Res. 2023 Dec 26;12(12):2505-2519. doi: 10.21037/tlcr-23-658. Epub 2023 Nov 22.

Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review.

Front Oncol. 2023 Nov 1;13:1227980. doi: 10.3389/fonc.2023.1227980. eCollection 2023.

[Ceritinib as First-line Treatment for Advanced Lung Adenocarcinoma  with COX7A2L-ALK Fusion: A Case Report and Literature Review].

Zhongguo Fei Ai Za Zhi. 2023 Apr 20;26(4):319-324. doi: 10.3779/j.issn.1009-3419.2023.102.15.

Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report.

Discov Oncol. 2023 Apr 13;14(1):44. doi: 10.1007/s12672-023-00654-x.

Case Report: Identification of Two Rare Fusions, and , That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib.

Front Oncol. 2021 Aug 13;11:722843. doi: 10.3389/fonc.2021.722843. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献